哪里想瘦打哪里！FDA批准Kythera服用药物上市在即

你才双下巴，你全家都双下巴！所谓美的欲人皆有之。如果说赘肉是每一个希望拥有令人难忘身材的“妹纸”或“汉纸”的迷乱，那么一个笑料十足的双下巴却是是这些人的生死作对了。每一分钟，世界各地都有人为自己的一张大饼脸而不已烦恼，虽然拥有一个肉感十足的双下巴捏上去是挺有肉感的，但是还是有很多人的心理素质使其无法太重一个双下巴之重。您可千万别笑，这甚至已经成百上千一个浩大的市场需求。根据美国政府皮肤外科手术协会的调查研究显示，68%的加拿大人对自己的双下巴指出了“苦恼”之情。而有鉴于此，在在Kythera新公司向FDA提交了其专门消灭双下巴的彩妆注射的设计抑止生素ATX-101。这种抑止生素顺利完成了许多“胖纸”梦寐以求的功能，哪里想瘦打哪里，却是是驻点瘦身。不用以为这种近乎心地善良的抑止生素只是一个恶搞，在FDA下属的皮肤和眼科抑止生素秘书会的无记名投票选举中，专家可是以17：0的超高得票一致拥护其香港交易所。或许是因为这些专家中也有很多饱受双下巴之苦吧。FDA也将合作开发计划于本年的5月13日先前对其予以最后最终。如果一切顺利的话，Kythera新公司合作开发计划于本年上半年将该产品香港交易所，分析方法人士预估这一抑止生素的年销售额将有约3亿美元之多。随着彩妆抑止生素市场需求的逐渐增大，Kythera新公司却是是下了一步好棋。新公司于月内以8400万美元的价格从其前合作合作开发伙伴波鸿主导权收回了这种抑止生素的全部基本权利。而Kythera新公司也希望以此为亟欲在彩妆抑止生素市场需求中攻城拔寨。就在上个月，Kythera新公司和Actelion新公司订下重要性2700万美元的合作合作开发双方同意，合作合作开发一种不甘心过的抑止炎症抑止生素，而这种抑止生素被确信意味著合作开发出一种治疗脱发的抑止生素。详细英文报道：Kythera ($KYTH) won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment.The agency's independent Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 that the drug's benefits outweighed its risks for patients looking to reduce submental fat, or double chin. The FDA is not required to follow its panels' votes, though it most commonly does, and the agency has promised to make a final decision on the injection by May 13. If all goes according to plan, Kythera plans to launch the drug, ATX-101, in the second half of this year.The biotech's shares he more than tripled since it pulled off a $73 million IPO in 2012, rising steadily as investors bet ATX-101 can carve out a space on the aesthetic market and potentially lure a Big Pharma acquirer. Kythera is pitching the injection as a much-needed nonsurgical option for double chin reduction, citing an American Society for Dermatologic Surgery survey that estimates 68% of Americans are "bothered" by submental fat.Kythera regained full rights to ATX-101's potential last year, orchestrating an $84 million deal to buy out ex-partner Bayer. And the drug, a synthetic version of the fat-blasting deoxycholic acid, could bring in more than $300 million a year once approved, Leerink yst Seamus Fernandez has said."This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation," Kythera CEO Keith Leonard said in a statement. "At Kythera, we remain focused on investing in novel treatments that will allow aesthetic physicians to better meet the needs of their patients."Kythera is also focused on raising some cash now that it has a likely approval ahead. The biotech filed for a $125 million offering as soon as the market closed on Monday. Its share price was down several points at the end of the day.Beyond its top prospect, Kythera is working to build out a pipeline of aesthetic medicines. Last month, the California biotech signed a $27 million deal with Actelion ($ATLN) to get its hands on a once-failed anti-inflammatory medicine that could he a future as a treatment for hair loss.